Thrombotic thrombocytopenic purpura and systemic lupus erythematosus

DAVID A FOX, JAMES D FAIX, JON COBLYN, PATRICIA FRASER, BRIAN SMITH, AND MICHAEL E WEINBLATT

From the Departments of Rheumatology and Immunology, Pathology, and Medicine, Brigham and Women’s and Beth Israel Hospitals, Harvard Medical School, Boston, Massachusetts

SUMMARY We report two patients with systemic lupus erythematosus who subsequently developed thrombotic thrombocytopenic purpura. In each case the coexistence of these two conditions was confirmed by pathological findings. Both patients responded to treatment, but one eventually died. A review of the literature suggests a possible relationship between the two disorders.

Key words: rheumatology, blood coagulation disorders, collagen diseases, plasmapheresis, cyclophosphamide.

Thrombotic thrombocytopenic purpura (TTP) is a rare clinical syndrome of unknown cause characterised by the pentad of microangiopathic haemolytic anaemia, thrombocytopenic purpura, neurological abnormalities, fever, and renal dysfunction.\(^1\)\(^-\)\(^3\) Patients with systemic lupus erythematosus (SLE), however, may develop similar clinical findings. We report two patients with pre-existing SLE whose course was complicated by the development of TTP.

Case reports

CASE 1

A 40 year old woman was diagnosed in 1977 as having seropositive rheumatoid arthritis and was treated with anti-inflammatory agents and sodium aurothiomalate. Over the next 18 months she developed a malar rash, Raynaud’s phenomenon, alopecia, and a positive antinuclear antibody (ANA) test. In September 1979 she was hospitalised with fever, headache, purpura, a malar rash, petechiae, hepatosplenomegaly, and symmetrical polyarthritis. The urinalysis showed 3+ proteinuria and haematuria without red cell casts. Haemoglobin was 68 g/l, white blood cell count 8000/mm\(^3\) (8\(\times\)10\(^9\)/l) with a left shift, platelet count 13 000/mm\(^3\) (13\(\times\)10\(^9\)/l), reticulocyte count 14%, and sedimentation rate 130 mm/1st h. The peripheral smear showed many schistocytes and nucleated red cells. Prothrombin time and partial thromboplastin time were normal. Biochemical tests included creatinine 0-8 mg/dl (71 \(\mu\)mol/l), lactic dehydrogenase (LD) 1120 IU/l, and bilirubin 6-4 mg/dl (109 \(\mu\)mol/l). The ANA test was positive at a titre of 1/40 with a peripheral and diffuse pattern. Anti-double stranded DNA antibodies were not detected. Total haemolytic complement, C3, and C4 were all depressed. Direct and indirect Coombs’ tests and assays for antiplatelet antibodies were negative. A diagnosis of thrombotic thrombocytopenic purpura was made, though a gingival biopsy was negative. Treatment was initiated with methylprednisolone 100 mg/day, aspirin, dipyriramole, and multiple courses of plasma exchange. Despite these measures there was no improvement in the patient’s clinical or haematological parameters, and a splenectomy was performed. Temporary improvement followed, with stabilisation of her haemoglobin and platelet count. Three days after discharge the patient relapsed with fever, haemolytic anaemia, and profound thrombocytopenia. She improved with plasmapheresis and methylprednisolone (100 mg/day), and over the next few months the amount of steroids was slowly reduced and eventually discontinued. Two months later she again relapsed. She responded to a repeat course of high dose steroids combined with plasma infusions but developed complications of steroid...
therapy, including hypertension and hyperglycaemia. Azathioprine was added when a reduction in steroid dose was followed by another relapse. Despite temporary improvement thrombocytopenia and fever recurred, and cyclophosphamide was begun at a dose of 200 mg daily. A clinical and haematological remission of the patient’s TTP has since been maintained for over five years. For 42 months she received prednisone, 5 mg every other day, and daily cyclophosphamide in slowly tapering doses. Both medications were eventually discontinued without further flares of TTP. Her polyarthritis has subsided and there is no evidence of active SLE.

CASE 2
A 42 year old women developed SLE in 1977, manifested by polyarthritis, Raynaud’s phenomenon, malar rash, pleuritis, membranous glomerulonephritis, and an ANA titre of 1/10 000 with a homogeneous and speckled pattern. Antibody to double stranded DNA was present and complement components were depressed. She was treated with prednisone and improved, but over the next three years she was hospitalised on multiple occasions for fever, psychosis, and seizures. In November 1981 she was hospitalised because of three days of headache and abdominal pain, preceded by one week of arthralgias, myalgias, and malaise. Her temperature was 103°F, and palatal and conjunctival haemorrhages were present. Alopecia and superficial pharyngeal erosions were noted. The haemoglobin was 69 g/l, platelet count 9000/mm² (9×10⁹/l), and white blood cell count 17 000/mm³ (17×10⁹/l). Total haemolytic complement, C3, and C4 were normal, though hypocomplementaemia had been present during previous SLE flares. Prothrombin time and partial thromboplastin time were normal. The peripheral blood smear showed many schistocytes and the LD was markedly raised. Bone marrow examination showed hyperplasia of all cell lines. The diagnosis of TTP was confirmed by gingival biopsy.

Treatment was initiated with methylprednisolone 60 mg/day, aspirin 1200 mg/day, dipyridamole 600 mg/day, and multiple courses of plasmapheresis. Over the next week the platelet count normalised and the peripheral smear, haemoglobin, and reticulocyte count improved. A sudden episode of aphasia occurred but resolved after plasmapheresis. The patient remained stable after discharge from the hospital on prednisone, aspirin, and dipyridamole. In late December 1981 she abruptly stopped all medication and one week later developed fever, acute abdominal pain, profound thrombocytopenia, and anaemia. The peripheral smear again showed many schistocytes and helmet cells. Despite corticosteroids, antiplatelet agents, and plasmapheresis the patient died.

Pathology

Characteristic histopathological features of both TTP and SLE were present in both patients. Although a gingival biopsy in case 1 did not show the haemalised thrombi of TTP, granular staining for both IgM and IgG characteristic of SLE was noted along the basement membrane by direct immunofluorescence. Similar deposits of IgM and IgG were seen in biopsy specimens of both sun exposed and non-sun exposed skin. The splenectomy specimen showed both the periarterial fibrosis of SLE and scattered hyaline thrombi typical of TTP (Fig. 1). In
Thrombotic thrombocytopenic purpura and systemic lupus erythematosus

case 2 the gingival biopsy specimen contained both intraluminal and subendothelial thrombi in a subepithelial artery. There was no significant stromal inflammation. At autopsy, in addition to membranous glomerulonephritis and splenic periarterial fibrosis characteristic of SLE, there were intraluminal and subendothelial hyaline thrombi within small arteries and arterioles of many organs, including heart, liver, spleen, kidneys, adrenals, lymph nodes, thyroid, pancreas, intestines, appendix, pituitary, choroid plexus, and brain. There was no evidence of vasculitis. The thrombi were especially prominent in the heart (Fig. 2). Although no definite myocardial infarction was identified grossly or microscopically, focal areas of red blood cell extravasation were seen.

Discussion

In this report we describe two patients with SLE who also developed TTP. Both patients fulfilled the 1982 American Rheumatism Association (ARA) criteria for the classification of SLE and showed splenic periarterial fibrosis. Both developed syndromes characteristic of TTP and were found to have multiple visceral subendothelial hyaline thrombi. Gingival biopsies, when positive, are helpful in confirming the diagnosis of TTP, but they lack both sensitivity and specificity. Similarly, the finding of hyaline thrombi in small arteries and arterioles in the spleen and in other organs, though characteristic of TTP, may be present in other disorders, especially disseminated intravascular coagulation (DIC). Various histological features have been proposed as relatively specific markers for TTP. These include subendothelial (as opposed to only intraluminal) thrombi, microaneurysm formation, and severe endothelial cell proliferation within microaneurysms (creating so called ‘glomeruloid bodies’). These have not been shown to be reliable in differentiating TTP from DIC pathologically. Concentric adventitial fibrosis around central and penicillary arteries of the spleen, especially when diffuse and severe, can be considered pathognomonic of SLE. Coexistence of these ‘onion skinning’ lesions with hyaline thrombi in the spleen has been reported in cases of SLE associated with TTP.

When prior reports of the association of SLE and TTP are analysed by the 1982 ARA criteria for SLE only four patients can be identified who had unequivocal SLE clinically and subsequently developed TTP. A fifth patient developed both SLE and TTP concurrently. In addition to the small number of cases in which the coexistence of SLE and TTP can be considered well established, there are additional reports linking SLE and TTP in which either the clinical or the pathological evidence for SLE is not conclusive. Levine and Shearn reviewed 151 cases of TTP reported before 1964 and noted that 34 patients (23%) had pathological finding suggestive of SLE. In most of these cases, however, Libman-Sacks endocarditis was the sole finding thought to indicate SLE. Nevertheless, eight patients did have splenic periadventitial fibrosis, seven had evidence of proliferative glomerulonephritis, and five had a positive LE cell test. Clinical information is incomplete for many of the patients, but it is likely that some did indeed have both SLE and TTP.

Recently Dixit et al reported a patient with probable SLE, C2 deficiency, and relapsing TTP, though the diagnosis of TTP was not confirmed histologically. One of our two patients presented with hypocomplementaemia at the time of her initial episode of TTP but had a normal total haemolytic complement, C2, C3, and C4 on other occasions. Our other patient had normal complement levels at the time of her TTP despite previous periods of hypocomplementaemia in conjunction with activity of her SLE. Thus it appears that in patients with SLE and TTP the complement profile is quite heterogeneous.

Although TTP occasionally complicates the course of SLE, the pathogenesis of TTP in these patients is not well understood. Patients with SLE may develop disturbances in blood coagulation, and lupus patients with circulating anticoagulants may be at risk for thrombotic events. Some patients with SLE who developed TTP had a history of prior thrombophlebitis. As yet, the relationship of these observations to the occurrence of TTP in SLE is unclear. In our patients a lupus anticoagulant was not detected and the titre of anticardiolipin antibodies was not determined.

There is little evidence connecting the immunological abnormalities of SLE with the occurrence of TTP. Circulating immune complexes had been detected during a prior flare of SLE in one report but were absent when TTP developed. In that patient SLE was clinically inactive when TTP occurred, but other patients have developed TTP during a flare of SLE. The diagnosis of TTP may be difficult and particular problems arise in patients with SLE because of the overlapping manifestations of the two disorders. Anaemia, thrombocytopenia, fever, neurological abnormalities, and renal disease all occur in SLE as well as in TTP, but a microangiopathic peripheral blood smear should alert the clinician to the possibility of TTP.

The prognosis of patients with TTP is guarded,
even when corticosteroids and splenectomy are employed.\textsuperscript{1, 2} The majority of patients previously reported with TTP and SLE died of TTP. The introduction of plasmapheresis or plasma infusion (or both) and the use of antithrombin agents appears to have improved the management of TTP, but relapses may occur despite good initial responses. Our first patient had a chronic course, required splenectomy, and eventually stabilised on cyclophosphamide. The second patient relapsed and died after discontinuing her medications. Microthrombi in the heart, similar to those seen in case 2, may account for cardiac death in TTP in the absence of either clinical or pathological signs of myocardial ischaemia, perhaps by affecting the conducting system.\textsuperscript{23} Dr Fox was supported by a postdoctoral fellowship of the Arthritis Foundation.

References